Generated by All in One SEO v5.0.1.1, this is an llms.txt file, used by LLMs to index the site.

# RCT1100-102

A Phase 1b Open-Label Study to Assess RCT1100 in DNAI-1 PCD Patients

## Sitemaps

- [XML Sitemap](https://pcd-clinical-studies.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT1100 for the Treatment of Primary Ciliary Dyskinesia](https://pcd-clinical-studies.com/recode-therapeutics-receives-u-s-fda-orphan-drug-designation-for-rct1100-for-the-treatment-of-primary-ciliary-dyskinesia/) - ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that company management will participate in the upcoming May conferences.
- [New Article Published in Science Highlights the Potential of ReCode Therapeutics’ Systemic Lung Delivery and CFTR Gene Correction](https://pcd-clinical-studies.com/new-article-published-in-science-highlights-the-potential-of-recode-therapeutics-systemic-lung-delivery-and-cftr-gene-correction/) - ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that company management will participate in the upcoming May conferences.
- [Scientist II, Chemistry](https://pcd-clinical-studies.com/director-process-development-mrna-production/) - Menlo Park, CA
- [ReCode Therapeutics Announces Appointment of Dean J. Mitchell as Chairman of its Board of Directors](https://pcd-clinical-studies.com/recode-therapeutics-announces-appointment-of-dean-j-mitchell-as-chairman-of-its-board-of-directors/) - ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that company management will participate in the upcoming May conferences.
- [ReCode Therapeutics to Participate in May Conferences](https://pcd-clinical-studies.com/recode-therapeutics-to-participate-in-may-conferences/) - ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that company management will participate in the upcoming May conferences.
- [Senior Scientist / Principal Scientist, Cell Biology – Lung Epithelia](https://pcd-clinical-studies.com/associate-director-clinical-operations-cystic-fibrosis/) - Menlo Park, CA
- [Senior/Executive Director, Translational Sciences & Nonclinical Operations](https://pcd-clinical-studies.com/associate-director-director-cmc-project-management/) - Menlo Park, CA
- [ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Study of Inhaled mRNA-Based Genetic Medicine, RCT2100, for the Treatment of Cystic Fibrosis](https://pcd-clinical-studies.com/recode-therapeutics-announces-first-participants-dosed-in-a-phase-1-healthy-volunteer-clinical-study-of-inhaled-mrna-based-genetic-medicine-rct2100-for-the-treatment-of-cystic-fibrosis/) - ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announcedthat the first cohort of healthy volunteer participants have been dosed in a Phase 1 clinical study of RCT2100, an inhaled mRNA-based investigational therapy for cystic fibrosis (CF) that focuses specifically on the 10-13% of patients with nonsense mutations that do not respond to or experience side effects with, approved CFTR modulators.
- [ReCode Therapeutics to Participate in February Conferences](https://pcd-clinical-studies.com/recode-therapeutics-to-participate-in-february-conferences/) - ReCode today announced that company management will participate in the upcoming February conferences... ReCode Therapeutics today announced that company management will participate in the upcoming February conferences...
- [Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis](https://pcd-clinical-studies.com/intellia-therapeutics-and-recode-therapeutics-announce-strategic-collaboration-to-develop-novel-gene-editing-therapies-for-cystic-fibrosis/) - Collaboration combines Intellia’s leading CRISPR-based platform, including its DNA writing technology, with ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP)to extend the reach of gene editing to disease-causing targets in the lung.
- [ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy for the Treatment of Primary Ciliary Dyskinesia](https://pcd-clinical-studies.com/recode-therapeutics-doses-first-patient-in-phase-1-clinical-study-of-novel-mrna-based-therapy-for-the-treatment-of-primary-ciliary-dyskinesia/) - – Phase 1 study aims to evaluate safety and tolerability of a single ascending dose of RCT1100 in patients with PCD caused by mutations in the DNAI1 gene – – RCT1100 is the first clinical evaluation of an inhaled mRNA-based therapy designed to restore ciliary function in people with PCD – Menlo Park, Calif. –
- [On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles](https://pcd-clinical-studies.com/on-the-mechanism-of-tissue-specific-mrna-delivery-by-selective-organ-targeting-nanoparticles/) - PNAS
- [The interplay of quaternary ammonium lipid structure and protein corona on lung-specific mRNA delivery by selective organ targeting (SORT) nanoparticles](https://pcd-clinical-studies.com/the-interplay-of-quaternary-ammonium-lipid-structure-and-protein-corona-on-lung-specific-mrna-delivery-by-selective-organ-targeting-sort-nanoparticles/) - Journal of Controlled Release
- [Lung SORT LNPs enable precise homology-directed repair mediated CRISPR/Cas genome correction in cystic fibrosis models](https://pcd-clinical-studies.com/lung-sort-lnps-enable-precise-homology-directed-repair-mediated-crispr-cas-genome-correction-in-cystic-fibrosis-models/) - Nature Communications
- [Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery](https://pcd-clinical-studies.com/preparation-of-selective-organ-targeting-sort-lipid-nanoparticles-lnps-using-multiple-technical-methods-for-tissue-specific-mrna-delivery/) - Nature Protocols
- [Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing](https://pcd-clinical-studies.com/selective-organ-targeting-sort-nanoparticles-for-tissue-specific-mrna-delivery-and-crispr-cas-gene-editing/) - Nature Nanotechnology
- [ReCode Therapeutics to Participate in November Conferences](https://pcd-clinical-studies.com/recode-therapeutics-to-participate-in-november-conferences/) - Menlo Park, Calif. – Nov. 10, 2023 – ReCode Therapeutics, a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics, today announced that company management will participate in the upcoming November conferences: Stifel 2023 Healthcare Conference Format: Company PresentationDate: November 14, 2023Time: 4:10 p.m. ETLocation: New York
- [Unshackling genetic medicines by enabling delivery beyond the liver](https://pcd-clinical-studies.com/unshackling-genetic-medicines-by-enabling-delivery-beyond-the-liver/) - Nature Biopharma Dealmakers
- [Aerosolized Therapy Restores CFTR in Patient-derived Cells](https://pcd-clinical-studies.com/aerosolized-therapy-restores-cftr-in-patient-derived-cells/) - Cystic Fibrosis News Today
- [Scientist II, Gene Editing](https://pcd-clinical-studies.com/principal-scientist-gene-correction/) - Durham, NC
- [ReCode Therapeutics Announces Closing of Extension to Series B Financing](https://pcd-clinical-studies.com/recode-therapeutics-announces-closing-of-extension-to-series-b-financing/) - – Total of $260 million in Series B funding includes an additional $50 million from existing and new investors, Bioluminescence Ventures and Solasta Ventures – Menlo Park, Calif. – Sept. 19, 2023 – ReCode Therapeutics, a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics, today
- [ReCode Therapeutics to Present at September Investor Conferences](https://pcd-clinical-studies.com/recode-therapeutics-to-present-at-september-investor-conferences/) - Menlo Park, Calif. – September 7, 2023 – ReCode Therapeutics, a clinical-stage company powering the next wave of genetic medicines, today announced that Company management will participate in the following upcoming investor conferences in September 2023: Morgan Stanley Global Healthcare Conference:Format: Company PresentationDate: September 12, 2023Time: 12:55 p.m. ETPresenter: David J. Lockhart, Ph.D., President & Chief Scientific Officer of
- [Recode Therapeutics Appoints Erica Jefferson as Senior Vice President of Corporate Affairs](https://pcd-clinical-studies.com/recode-therapeutics-appoints-erica-jefferson-as-senior-vice-president-of-corporate-affairs/) - ReCode Therapeutics strengthens leadership team with appointment of Erica Jefferson as Senior Vice President of Corporate Affairs.
- [ReCode Therapeutics to Present at Jefferies Healthcare Conference](https://pcd-clinical-studies.com/recode-therapeutics-to-present-at-jefferies-healthcare-conference/) - Menlo Park, Calif. – June 2, 2023 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that Angèle Maki, Ph.D., Senior Vice President, Business Development of ReCode Therapeutics, will present a company overview at 8:30 a.m. ET on Friday, June 9,
- [Seven technologies to watch in 2022](https://pcd-clinical-studies.com/seven-technologies-to-watch-in-2022/) - Nature
- [ReCode Therapeutics to Present at Oppenheimer 32nd Annual Healthcare Conference](https://pcd-clinical-studies.com/recode-therapeutics-to-present-at-oppenheimer-32nd-annual-healthcare-conference/) - Menlo Park, Calif. and Dallas, Texas – March 9, 2022 – ReCode Therapeutics, a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary selective organ targeting (SORT) LNP delivery platform, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil, chief executive officer of ReCode Therapeutics will present a corporate overview at the upcoming Oppenheimer 32nd Annual
- [ReCode Therapeutics Corporate Presentation](https://pcd-clinical-studies.com/recode-therapeutics-corporate-presentation/) - Oppenheimer 32nd Annual Healthcare Conference
- [ReCode Therapeutics to Present Preclinical Data Using Proprietary SORT LNP Delivery Platform from its mRNA-based Therapeutic Programs at the ATS 2022 International Conference in San Francisco](https://pcd-clinical-studies.com/recode-therapeutics-to-present-preclinical-data-using-proprietary-sort-lnp-delivery-platform-from-its-mrna-based-therapeutic-programs-at-the-ats-2022-international-conference-in-san-francisco/) - Menlo Park, Calif. and Dallas, Texas – May 3, 2022 – ReCode Therapeutics, a biopharmaceutical company pioneering disease-modifying genetic medicines using its selective organ targeting (SORT) lipid nanoparticles (LNP) delivery platform, today announced that it will present preclinical data from its mRNA-based therapeutic programs in cystic fibrosis and primary ciliary dyskinesia at the American Thoracic
- [ReCode Therapeutics to Present at 2022 RBC Capital Markets Global Healthcare Conference](https://pcd-clinical-studies.com/recode-therapeutics-to-present-at-2022-rbc-capital-markets-global-healthcare-conference/) - Menlo Park, Calif. and Dallas, Texas – May 10, 2022 – ReCode Therapeutics, a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary selective organ targeting (SORT) lipid nanoparticle (LNP) delivery platform, today announced that David Lockhart, Ph.D., President & Chief Scientific Officer of ReCode Therapeutics, will participate in a fireside chat on Tuesday, May
- [Rescue of Ciliary Function in Cell-based Primary Ciliary Dyskinesia Models using Nebulized, LNP-formulated mRNA](https://pcd-clinical-studies.com/rescue-of-ciliary-function-in-cell-based-primary-ciliary-dyskinesia-models-using-nebulized-lnp-formulated-mrna/) - American Thoracic Society (ATS) 2022 International Conference
- [Optimization of DNAI1 mRNA Constructs to Treat Primary Ciliary Dyskinesia](https://pcd-clinical-studies.com/optimization-of-dnai1-mrna-constructs-to-treat-primary-ciliary-dyskinesia/) - American Thoracic Society (ATS) 2022 International Conference
- [ReCode Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference](https://pcd-clinical-studies.com/recode-therapeutics-to-present-at-40th-annual-j-p-morgan-healthcare-conference/) - Menlo Park, Calif. and Dallas, Texas – January 10, 2022 – ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary selective organ targeting (SORT) LNP delivery platform, today announced that Company leadership will present virtually at the 40th Annual J.P. Morgan Healthcare Conference. Presentation details: Date: Thursday, January 13, 2022
- [ReCode Therapeutics Appoints Shehnaaz Suliman, M.D., MBA, M.Phil., as Chief Executive Officer](https://pcd-clinical-studies.com/recode-therapeutics-appoints-shehnaaz-suliman-m-d-mba-m-phil-as-chief-executive-officer/) - Dr. Suliman brings over 25 years of drug development, deal-making and company building expertise as ReCode continues advancing its pipeline of novel genetic medicines using its powerful selective organ targeting (SORT) LNP delivery platform Menlo Park, Calif. And Dallas, Texas – January 10, 2022 – ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic
- [An mRNA-Based Therapy to Treat Primary Ciliary Dyskinesia: Aerosol Delivery, Biodistribution and Tolerability](https://pcd-clinical-studies.com/an-mrna-based-therapy-to-treat-primary-ciliary-dyskinesia-aerosol-delivery-biodistribution-and-tolerability/) - American Thoracic Society (ATS) 2022 International Conference
- [Functional Rescue of CFTR by Aerosolized Delivery of Optimized CFTR mRNA Using ReCode LNPs in Primary Human Bronchial Epithelial Cells Derived From Patients With Cystic Fibrosis](https://pcd-clinical-studies.com/functional-rescue-of-cftr-by-aerosolized-delivery-of-optimized-cftr-mrna-using-recode-lnps-in-primary-human-bronchial-epithelial-cells-derived-from-patients-with-cystic-fibrosis/) - American Thoracic Society (ATS) 2022 International Conference
- [ReCode Therapeutics Presents Preclinical Data from Inhaled mRNA Therapeutic Program in Primary Ciliary Dyskinesia (PCD) in Three Posters at the ATS 2022 International Conference](https://pcd-clinical-studies.com/recode-therapeutics-presents-preclinical-data-from-inhaled-mrna-therapeutic-program-in-primary-ciliary-dyskinesia-pcd-in-three-posters-at-the-ats-2022-international-conference/) - ReCode’s Selective Organ Targeting (SORT) lipid nanoparticle (LNP) formulation of DNAI1 mRNA was successfully and directly delivered to lungs as an inhaled aerosol with no significant exposure to other tissues SORT LNP-formulated DNAI1 mRNA demonstrates long-lasting functional recovery and is well-tolerated with rapid clearance of LNP lipids allowing repeat administration ReCode to present new preclinical
- [ReCode Therapeutics to Participate in Upcoming July Investor Conferences](https://pcd-clinical-studies.com/recode-therapeutics-to-participate-in-upcoming-july-investor-conferences/) - Menlo Park, Calif. and Dallas, Texas – July 6, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that Company leadership will participate in two upcoming investor conferences in July: William Blair Biotech Focus Conference (New York, NY)Format: Panel PresentationDate:
- [SORTing It Out: ReCode Expands Beyond Respiratory Disorders](https://pcd-clinical-studies.com/genetic-engineering-biotech-news/) - Genetic Engineering & Biotechnology News
- [Peninsula company raises $120M to build new vehicles for mRNA drugs, other therapies](https://pcd-clinical-studies.com/peninsula-company-raises-120m-to-build-new-vehicles-for-mrna-drugs-other-therapies/) - San Francisco Business Times
- [ReCode Therapeutics Raises $200M in Series B](https://pcd-clinical-studies.com/recode-therapeutics-raises-200m-in-series-b/) - Inside Precision Medicine
- [Pfizer, Sanofi-backed LNP outfit goes back to the well and draws $120M for its trek to the clinic](https://pcd-clinical-studies.com/pfizer-sanofi-backed-lnp-outfit-goes-back-to-the-well-and-draws-120m-for-its-trek-to-the-clinic/) - Endpoints News
- [ReCode breaks the mold with $120M financing, bringing clutch of Big Pharmas along for ride](https://pcd-clinical-studies.com/recode-breaks-the-mold-with-120m-financing-bringing-clutch-of-big-pharmas-along-for-ride/) - Fierce Biotech
- [ReCode Raises Another $120m To Broaden LNP Delivery Of Genetic Medicines](https://pcd-clinical-studies.com/recode-raises-another-120m-to-broaden-lnp-delivery-of-genetic-medicines/) - Scrip Pharma Intelligence
- [ReCode Therapeutics to Expand Next-Generation Delivery Platform and Diversify Genetic Medicines Pipeline with Oversubscribed Series B Financing Totaling $200M](https://pcd-clinical-studies.com/recode-therapeutics-to-expand-next-generation-delivery-platform-and-diversify-genetic-medicines-pipeline-with-oversubscribed-series-b-financing-totaling-200m/) - – Series B extension co-led by AyurMaya, an affiliate of Matrix Capital Management, and Leaps by Bayer, with participation from Amgen Ventures. Adds to Existing Investors, including Pfizer Ventures, EcoR1 Capital and Sanofi Ventures. – – Proceeds to expand and diversify platform and pipeline to include mRNA and gene correction therapeutics for central nervous system,
- [ReCode Therapeutics Presents New Preclinical Data from mRNA-based Program for Cystic Fibrosis at the ATS 2022 International Conference](https://pcd-clinical-studies.com/recode-therapeutics-presents-new-preclinical-data-from-mrna-based-program-for-cystic-fibrosis-at-the-ats-2022-international-conference/) - Study confirms the ability of ReCode’s Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform to deliver optimized, functional CFTR mRNA as an aerosol directly to specific cell targets Results show consistent rescue of CFTR function across multiple cystic fibrosis patient genotypes, including genotypes that do not respond to approved CFTR modulator treatments Menlo Park, Calif.
- [See the 13-slide pitch deck a biotech used to raise $120M and write the next chapter in mRNA medicines](https://pcd-clinical-studies.com/see-the-13-slide-pitch-deck-a-biotech-used-to-raise-120m-and-write-the-next-chapter-in-mrna-medicines/) - Business Insider
- [ReCode Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference](https://pcd-clinical-studies.com/recode-therapeutics-to-present-at-morgan-stanley-20th-annual-global-healthcare-conference/) - MENLO PARK, Calif. & DALLAS--(BUSINESS WIRE)--ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today that Shehnaaz Suliman, M.D., M.B.A., M.Phil., Chief Executive Officer of ReCode Therapeutics, will present a corporate overview at 8:00 a.m. ET on Tuesday, September 13th at the upcoming
- [Fierce Biotech's 2022 Fierce15](https://pcd-clinical-studies.com/fierce-biotechs-2022-fierce15/) - Fierce Biotech
- [Fierce Biotech Names ReCode Therapeutics as One of its “Fierce 15” Biotech Companies of 2022](https://pcd-clinical-studies.com/fierce-biotech-names-recode-therapeutics-as-one-of-its-fierce-15-biotech-companies-of-2022/) - Fierce Biotech has named ReCode Therapeutics as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.
- [ReCode Therapeutics to Present at Jefferies Cell and Genetic Medicine Summit](https://pcd-clinical-studies.com/recode-therapeutics-to-present-at-jefferies-cell-and-genetic-medicine-summit/) - Menlo Park, Calif. and Dallas, Texas – September 22, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that David Lockhart, Ph.D, President and Chief Scientific Officer of ReCode Therapeutics, will present a company overview at 8:00 a.m. ET on
- [ReCode Therapeutics to Participate in Upcoming October Investor Conferences](https://pcd-clinical-studies.com/recode-therapeutics-to-participate-in-upcoming-october-investor-conferences/) - Menlo Park, Calif. and Dallas, Texas – September 26, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today that Company leadership will participate in two upcoming investor conferences in October: Chardan’s 6th Annual Genetic Medicines ConferenceFormat: Company PresentationDate: Monday, October
- [ReCode Therapeutics to Participate in Upcoming November Investor Conferences](https://pcd-clinical-studies.com/recode-therapeutics-to-participate-in-upcoming-november-investor-conferences-2/) - Menlo Park, Calif. and Dallas, Texas – November 2, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today that Company leadership will participate in two upcoming investor conferences in November: Credit Suisse 31st Annual Healthcare ConferenceFormat: Company PresentationDate: Wednesday, November
- [Rescue of Ciliary Function in Primary Ciliary Dyskinesia using Nebulized LNP-formulated DNAI1 mRNA](https://pcd-clinical-studies.com/rescue-of-ciliary-function-in-primary-ciliary-dyskinesia-using-nebulized-lnp-formulated-dnai1-mrna/) - 5th European Cilia Conference
- [ReCode Therapeutics Company Overview](https://pcd-clinical-studies.com/41st-annual-j-p-morgan-healthcare-conference/) - 41st Annual J.P. Morgan Healthcare Conference
- [ReCode Therapeutics to Present at Upcoming Investor Conferences in 2022](https://pcd-clinical-studies.com/recode-therapeutics-to-present-at-upcoming-investor-conferences-in-2022/) - Menlo Park, Calif. and Dallas, Texas – November 22, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today that Company leadership will participate in two upcoming investor conferences in November: Piper Sandler 34th Annual Healthcare ConferenceFormat: Company PresentationDate: Tuesday, November
- [ReCode Therapeutics Appoints Trisha Millican to Board of Directors](https://pcd-clinical-studies.com/recode-therapeutics-appoints-trisha-millican-to-board-of-directors/) - Veteran life sciences industry financial executive appointed as independent member of the Board of Directors Menlo Park, Calif. and Dallas, Texas – December 1, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today the appointment of Patricia “Trisha” Millican to
- [Ep124: Shehnaaz Suliman on Delivery of Genetic Medicines](https://pcd-clinical-studies.com/ep124-shehnaaz-suliman-on-delivery-of-genetic-medicines/) - The Long Run with Luke Timmerman
- [ReCode Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference](https://pcd-clinical-studies.com/recode-therapeutics-to-present-at-41st-annual-j-p-morgan-healthcare-conference/) - Menlo Park, Calif. – January 3, 2023 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that Shehnaaz Suliman, M.D., M.B.A., M.Phil., Chief Executive Officer of ReCode Therapeutics, will present a company overview at 9:00 a.m. PT on Tuesday, January 10,
- [ReCode Therapeutics Announces Strategic Collaboration with AskBio to Explore Single Vector Gene-Editing Platform](https://pcd-clinical-studies.com/recode-therapeutics-announces-strategic-collaboration-with-askbio-to-explore-single-vector-gene-editing-platform/) - Collaboration will combine ReCode’s unique delivery technology with AskBio’s gene editing and DNA cargoes to develop novel gene correction therapies for the liver and lung Menlo Park, Calif. – January 9, 2023 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today
- [Biotech backed by who’s who of Big Pharma nabs AskBio deal](https://pcd-clinical-studies.com/fda-accepts-one-delays-another-data-deals-and-dollars-for-slate-of-biotechs/) - Endpoints News
- [ReCode Therapeutics Announces Strategic Investment from the Cystic Fibrosis Foundation to Accelerate Development of Novel mRNA Therapy](https://pcd-clinical-studies.com/recode-therapeutics-announces-strategic-investment-from-the-cystic-fibrosis-foundation-to-accelerate-development-of-novel-mrna-therapy/) - Cystic Fibrosis Foundation will invest up to $15 million to help advance the development of ReCode’s CFTR mRNA therapy for cystic fibrosis Menlo Park, Calif.– January 10, 2023 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today that it will receive
- ['Beyond Vaccines': Biotech Is Booming in the Bay Area Despite a Cooling Economy](https://pcd-clinical-studies.com/recode-receives-cash-boost-for-cystic-fibrosis-program/) - KQED
- [ReCode Therapeutics Establishes Scientific Advisory Board](https://pcd-clinical-studies.com/recode-therapeutics-establishes-scientific-advisory-board/) - Members include distinguished academic and industry leaders with expertise in genetic medicine, delivery technology and drug development Menlo Park, Calif. and Dallas, Texas – November 14, 2022 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today the formation of the company's
- [Recode Therapeutics Expands Leadership Team with Appointment of April Loui as Senior Vice President of Quality and CMC Regulatory](https://pcd-clinical-studies.com/recode-therapeutics-expands-leadership-team-with-appointment-of-april-loui-as-senior-vice-president-of-quality-and-cmc-regulatory/) - Distinguished biotech industry veteran brings decades of experience to lead the scale-up of manufacturing capabilities for ReCode’s pipeline of first-in-class precision genetic medicines Menlo Park, Calif. – February 1, 2023 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced today the appointment of
- [Nebulized LNP-formulated DNAI1 mRNA Therapy to Restore Mucociliary Clearance for the Treatment of Primary Ciliary Dyskinesia](https://pcd-clinical-studies.com/nebulized-lnp-formulated-dnai1-mrna-therapy-to-restoremucociliary-clearance-for-the-treatment-of-primary-ciliary-dyskinesia/) - 2023 Cilia, Mucus and Mucociliary Interactions GRC
- [Aerosolized lipid nanoparticle/mRNA therapy to treat patients with Cystic Fibrosis](https://pcd-clinical-studies.com/aerosolized-lipid-nanoparticle-mrna-therapy-to-treat-patients-with-cystic-fibrosis/) - 2023 Cilia, Mucus and Mucociliary Interactions GRC
- [ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Trial of Novel Disease-Modifying Genetic Medicine, RCT1100 for the Treatment of Primary Ciliary Dyskinesia](https://pcd-clinical-studies.com/recode-therapeutics-announces-first-participants-dosed-in-a-phase-1-healthy-volunteer-clinical-trial-of-novel-disease-modifying-genetic-medicine-rct1100-for-the-treatment-of-primary-ciliary-dyskinesi/) - Phase 1 trial to evaluate safety and tolerability of a single ascending dose of RCT1100, an inhaled mRNA-based genetic medicine First clinical-stage candidate from ReCode’s proprietary SORT LNP delivery platform designed to restore ciliary function in the lungs of people with PCD caused by pathogenic mutations in the DNAI1 gene; IND submission planned for 2H23
- [ReCode Therapeutics to Present at BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines](https://pcd-clinical-studies.com/recode-therapeutics-to-present-at-bmo-biopharma-spotlight-series-novel-technologies-for-the-delivery-of-genetic-medicines/) - Menlo Park, Calif. – March 21, 2023 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that David Lockhart, Ph.D., President and Chief Scientific Officer of ReCode Therapeutics, will participate in a panel discussion titled “Novel LNPs Targeting Diverse Tissues” at
- [ReCode Therapeutics to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days](https://pcd-clinical-studies.com/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days/) - Menlo Park, Calif. – March 27, 2023 – ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that David Lockhart, Ph.D., President and Chief Scientific Officer of ReCode Therapeutics, will participate in a fireside chat at 9:35 a.m. ET on Monday, April
- [Recode Therapeutics Appoints John G. Matthews, MBBS, MRCP, Ph.D., as Senior Vice President, Clinical Development](https://pcd-clinical-studies.com/recode-therapeutics-appoints-john-g-matthews-mbbs-mrcp-ph-d-as-senior-vice-president-clinical-development/) - Renowned physician-scientist brings deep expertise in clinical development and inhaled drug delivery to ReCode as lead programs for primary ciliary dyskinesia and cystic fibrosis enter clinical trials
- [Best Places to Work in the Bay Area 2023](https://pcd-clinical-studies.com/best-places-to-work-in-the-bay-area-2023/) - San Francisco Business Times

## Pages

- [A Phase 1b Open-Label Study to Assess RCT1100 in DNAI-1 PCD Patients](https://pcd-clinical-studies.com/) - Find more information about the study, investigational medicine, and how you, or someone you know, can participate.
- [Cookie Policy](https://pcd-clinical-studies.com/cookie-policy/) - Last updated: October 2023This Policy describes how and why ReCode Therapeutics (“ReCode”, “we”, “us” or “our”) uses cookies on our website: https://pcd-clinical-studies.com/ (the “Website”). What are cookies?A cookie is a small piece of data (text file) that a website or app – when visited by a user – asks your browser to store on your device
- [Terms & Conditions](https://pcd-clinical-studies.com/terms-conditions/) - Read ReCode Therapeutics' terms of use.
- [Privacy Policy](https://pcd-clinical-studies.com/privacy-policy/) - Read ReCode Therapeutics' privacy policy.

## Categories

- [Press Releases](https://pcd-clinical-studies.com/category/press-releases/)
- [Presentations](https://pcd-clinical-studies.com/category/presentations/)
- [Publications](https://pcd-clinical-studies.com/category/publications/)
- [Careers](https://pcd-clinical-studies.com/category/careers/)
- [Featured](https://pcd-clinical-studies.com/category/featured/)

## Tags

- [American Thoracic Society (ATS)](https://pcd-clinical-studies.com/tag/american-thoracic-society-ats/)
- [Cilia2022](https://pcd-clinical-studies.com/tag/cilia2022/)
- [J.P. Morgan](https://pcd-clinical-studies.com/tag/j-p-morgan/)
- [Gordon Research Conferences](https://pcd-clinical-studies.com/tag/gordon-research-conferences/)
- [Featured](https://pcd-clinical-studies.com/tag/featured/)